Toxoplasmosis is a potentially life-threatening opportunistic infection after hematopoietic stem cell transplantation (HSCT). 1 It usually results from reactivation of latent infection in patients seropositive for Toxoplasma before transplantation, but transmission from the donor via the graft has been described. [2] [3] [4] A 44-year-old Algerian woman who had been in France for 2 years required allogeneic HSCT for relapsed AML from her HLA-identical brother in Algeria. The donor's pre-transplant Toxoplasma IgG antibody was positive and the IgM titer was very high. Diagnosis of recent toxoplasmosis was based on the serological profile (Table 1) . 5 The recipient's T. gondii serostatus was negative. Nevertheless, a decision was made to proceed with the allograft for medical reasons (recipient) and logistic reasons (donor). The aim of subsequent interventions and monitoring was to prevent toxoplasmosis in the recipient.
Starting 15 days before the graft, the donor was treated by spiramycin (9 MU/day) despite being asymptomatic. Table 1 shows that the detection of T. gondii DNA in blood was negative 4 and 10 days prior to stem cell harvest. PCR for T. gondii on the harvested stem cells was also negative.
The conditioning regimen consisted of cyclophosphamide and TBI. Cyclosporine and mycophenolate mofetil were used for GVHD prophylaxis. Pyrimethaminesulfadoxime was initiated as specific prophylaxis against toxoplasmosis after HSCT, and was administered for 15 days. The patient developed fever of unknown origin on day þ 3, and was treated with piperacillin-tazobactam and amikacin initially, with subsequent addition of teicoplanin. PCR for T. gondii DNA was negative on days þ 2, þ 9, þ 15 and þ 19 (Table 1) . IgG and IgM antibodies were detectable. Patient became afebrile on day þ 12. On day þ 15, pyrimethamine-sulfadoxime was changed to trimethoprim-sulfamethoxazole twice weekly.
Engraftment occurred on day þ 14. Grade 1 acute GVHD was seen. Full donor-type chimerism was demonstrated. Anti-Toxoplasma IgG and IgM titers decreased from day þ 31 to day þ 270. At 18 months after transplantation, the patient is alive and well, with no sign of chronic GVHD or toxoplasmosis.
Acute toxoplasmosis in a donor would normally be a reason to delay stem cell collection. However, as in our case, this may not be possible and the need for HSCT may be urgent. Under such circumstances, treating the donor and using pharmacoprophylaxis in the recipient with PCR monitoring 6, 7 may permit the transplant to proceed safely. The major risk is potential hematoplogic toxicity (myelosuppression) in the recipient. 4, 8 However, engraftment was prompt in our patient.
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